Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 approval for Sonrotoclax and 2027 approval for BGB16673, notes the analyst, who contends that Street estimates for BGB-16673 and Sonrotoclax are “too conservative.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONC:
Disclaimer & DisclosureReport an Issue